全文获取类型
收费全文 | 638篇 |
免费 | 37篇 |
国内免费 | 3篇 |
专业分类
耳鼻咽喉 | 7篇 |
儿科学 | 22篇 |
妇产科学 | 16篇 |
基础医学 | 85篇 |
口腔科学 | 27篇 |
临床医学 | 59篇 |
内科学 | 139篇 |
皮肤病学 | 17篇 |
神经病学 | 54篇 |
特种医学 | 7篇 |
外科学 | 56篇 |
综合类 | 7篇 |
预防医学 | 25篇 |
眼科学 | 70篇 |
药学 | 53篇 |
中国医学 | 12篇 |
肿瘤学 | 22篇 |
出版年
2023年 | 12篇 |
2022年 | 17篇 |
2021年 | 55篇 |
2020年 | 14篇 |
2019年 | 26篇 |
2018年 | 36篇 |
2017年 | 20篇 |
2016年 | 22篇 |
2015年 | 23篇 |
2014年 | 34篇 |
2013年 | 44篇 |
2012年 | 62篇 |
2011年 | 52篇 |
2010年 | 27篇 |
2009年 | 18篇 |
2008年 | 30篇 |
2007年 | 44篇 |
2006年 | 16篇 |
2005年 | 28篇 |
2004年 | 13篇 |
2003年 | 10篇 |
2002年 | 9篇 |
2001年 | 3篇 |
2000年 | 7篇 |
1999年 | 2篇 |
1998年 | 2篇 |
1995年 | 1篇 |
1994年 | 1篇 |
1993年 | 2篇 |
1992年 | 6篇 |
1991年 | 3篇 |
1990年 | 4篇 |
1989年 | 1篇 |
1988年 | 4篇 |
1987年 | 9篇 |
1986年 | 2篇 |
1985年 | 2篇 |
1984年 | 1篇 |
1983年 | 1篇 |
1981年 | 2篇 |
1979年 | 2篇 |
1978年 | 1篇 |
1974年 | 1篇 |
1973年 | 1篇 |
1945年 | 1篇 |
1944年 | 2篇 |
1943年 | 1篇 |
1942年 | 1篇 |
1900年 | 1篇 |
1899年 | 1篇 |
排序方式: 共有678条查询结果,搜索用时 15 毫秒
81.
82.
83.
O'Donnell CJ Kavousi M Smith AV Kardia SL Feitosa MF Hwang SJ Sun YV Province MA Aspelund T Dehghan A Hoffmann U Bielak LF Zhang Q Eiriksdottir G van Duijn CM Fox CS de Andrade M Kraja AT Sigurdsson S Elias-Smale SE Murabito JM Launer LJ van der Lugt A Kathiresan S;CARDIoGRAM Consortium Krestin GP Herrington DM Howard TD Liu Y Post W Mitchell BD O'Connell JR Shen H Shuldiner AR Altshuler D Elosua R Salomaa V Schwartz SM Siscovick DS Voight BF Bis JC Glazer NL Psaty BM Boerwinkle E Heiss G 《Circulation》2011,124(25):2855-2864
84.
Kakuda TN Abel S Davis J Hamlin J Schöller-Gyüre M Mack R Ndongo N Petit W Ridgway C Sekar V Tweedy S Hoetelmans RM 《Antimicrobial agents and chemotherapy》2011,55(5):2290-2296
The effects of darunavir-ritonavir at 600 and 100 mg twice daily (b.i.d.) alone, 200 mg of etravirine b.i.d. alone, or 600 and 100 mg of darunavir-ritonavir b.i.d. with 200 mg etravirine b.i.d. at steady state on the steady-state pharmacokinetics of maraviroc, and vice versa, in healthy volunteers were investigated in two phase I, randomized, two-period crossover studies. Safety and tolerability were also assessed. Coadministration of 150 mg maraviroc b.i.d. with darunavir-ritonavir increased the area under the plasma concentration-time curve from 0 to 12 h (AUC12) for maraviroc 4.05-fold relative to 150 mg of maraviroc b.i.d. alone. Coadministration of 300 mg maraviroc b.i.d. with etravirine decreased the maraviroc AUC12 by 53% relative to 300 mg maraviroc b.i.d. alone. Coadministration of 150 mg maraviroc b.i.d. with etravirine-darunavir-ritonavir increased the maraviroc AUC12 3.10-fold relative to 150 mg maraviroc b.i.d. alone. Maraviroc did not significantly affect the pharmacokinetics of etravirine, darunavir, or ritonavir. Short-term coadministration of maraviroc with darunavir-ritonavir, etravirine, or both was generally well tolerated, with no safety issues reported in either trial. Maraviroc can be coadministered with darunavir-ritonavir, etravirine, or etravirine-darunavir-ritonavir. Maraviroc should be dosed at 600 mg b.i.d. with etravirine in the absence of a potent inhibitor of cytochrome P450 3A (CYP3A) (i.e., a boosted protease inhibitor) or at 150 mg b.i.d. when coadministered with darunavir-ritonavir with or without etravirine. 相似文献
85.
86.
Thomas G. Heffron Todd Pillen Gregory Smallwood John Rodriguez Sundari Sekar Stuart Henry Miriam Vos Katherine Casper Nitika Arora Gupta Carlos G. Fasola Rene Romero 《Pediatric transplantation》2010,14(2):228-232
Heffron TG, Pillen T, Smallwood G, Rodriguez J, Sekar S, Henry S, Vos M, Casper K, Gupta NA, Fasola CG, Romero R. Pediatric liver transplantation for acute liver failure at a single center: A 10‐yr experience.Pediatr Transplantation 2010:14:228–232. © 2009 John Wiley & Sons A/S. Abstract: Children transplanted for ALF urgently require an optimal graft and have lower post‐transplant survival compared with children transplanted for chronic liver disease. Over 10 yr, 33 consecutive children transplanted for ALF were followed. Demographics, encephalopathy, intubation, dialysis, laboratory values, graft type ABOI, XL (GRWR > 5%), DDSLT, LDLT and WLT were evaluated. Complications and survival were determined. ALF accounted for 33/201 (16.4%) of transplants during this period. Twelve of 33 received ABOI, five XL grafts, 18 DDSLT, and three LDLT. Waiting time pretransplant was 2.1 days. One‐ and three‐yr patient survival in the ALF group was 93.4% and 88.9%, and graft survivals were 86.4% and 77.7%. Median follow‐up was 1452 days. ABOI one‐ and three yr patient and graft survival in the ALF was 91.6% and 78.6%. No difference in graft or patient survival was noted in the ALF and chronic liver disease group or the ABOI and the ABO compatible group. A combination of ABO incompatible donor livers, XL grafts, DDSLT, LDLT and WLT led to a short wait time and subsequent graft and patient survival comparable to patients with non‐acute disease. 相似文献
87.
88.
89.